Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
By S. Nissen, S. Nicholls, K. Wolski, R. Nesto, S. Kupfer, Alfonso T. Perez, H. Jure, R. de Larochellière, C. Staniloae, K. Mavromatis and 5 more. Journal of the American Medical Association (JAMA), 2008
890 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/5b3c663005057038d471a968982724acdb9889c4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 (2010, result): “Consistent with these trials, pioglitazone decreased carotid intima medial thickness [206] and coronary atherosclerotic plaque volume [207].”
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, result): “These molecular observations help to explain the recent results from the CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) (167) and PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) (168) studies, in w”
- Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (2014, background): “Compared to rosiglitazone, pioglitazone exerts beneficial effects on the plasma lipid profile, leading to a lower risk of acute myocardial infarction, stroke, or heart failure [99–103].”